血塞通联合依达拉奉治疗急性脑梗死的疗效及对患者血清超敏C反应蛋白、同型半胱氨酸、神经元特异性烯醇化酶的影响

目的探讨血塞通联合依达拉奉治疗急性脑梗死(ACI)的疗效及对患者血清超敏C反应蛋白(hsCRP)、同型半胱氨酸(Hcy)、神经元特异性烯醇化酶(NSE)的影响。方法入选2014年4月至2016年4月间我院收治的ACI患者112例,随机分成对照组(n=56)与观察组(n=56)。两组均给予常规治疗,对照组在常规治疗的基础上加用依达拉奉,而观察组在对照组的基础上再加用血塞通进行治疗,两组疗程均为2周。观察并记录治疗前后两组患者血清hs-CRP、Hcy、NSE水平的变化情况,神经功能缺损情况;同时对比两组的临床疗效,以及治疗期间不良反应发生情况。结果治疗后两组患者血清hs-CRP、Hcy、NSE水平及神经功能缺损(NHISS)评分均显著改善,且观察组改善情况优于对照组,差异均有统计学意义(P0.05);观察组患者的治疗总有效率为91.1%显著高于对照组的75.0%,差异有统计学意义(P0.05);此外,两组患者均未出现明显的不良反应。结论血塞通联合依达拉奉治疗ACI,能够显著改善患者的血清hs-CRP、Hcy、NSE水平,以及NHISS评分,其临床疗效显著,安全性高。

The Curative Effect of Xuesaitong Injection Combined with Edaravone in Treatment of Acute Cerebral Infarction Patients and Serum high-sensitivity C Reactive Protein,Homocysteine, Neuron Specific Enolase

Objective To investigate the effect of Xuesaitong combined with edaravone in treatment of acute cerebral infarction (ACI)and its effects on serum high-sensitivity C reactive protein (hs-CRP),homocysteine(Hcy),neuron specific enolase(NSE)effect.Methods 112 patients with ACI admitted to our hospital from April 2014 to April 2016 were randomly divided into control group (n =56) and observation group(n =56).Two groups were given conventional treatment,the control group on the basis of conventional treatment combined with edaravone,and the observation group on the basis of the control group were treated with Xuesaitong plus,two groups were treated for 2 weeks.To observe and record the changes of serum hs-CRP,Hcy,NSE levels of two groups of patients before and after treatment,neurological deficits,and compared the clinical efficacy of the two groups,as well as the incidence of adverse reactions during treatment.Results two groups of patients with serum hs-CRP,Hcy,NSE levels and neurological function after treatment(NHISS) scores were significantly improved,and the observation group improved better than the control group,the differences were statistically significant (P ＜ 0.05);the treatment group the total efficiency of 91.1％ was significantly higher than that in the control group 75 ％,with statistical significance the difference (P ＜ 0.05);in addition,there were no obvious adverse reactions in two groups.Conclusion Xuesaitong injection combined with edaravone in the treatment of ACI,can significantly improve the patient's serum hs-CRP,Hcy,NSE level and NHISS score,the clinical curative effect,high safety.